Syfovre safety check: Real-World study tracks eye drug in 300 patients

NCT ID NCT06161584

Ongoing Disease control Sponsor: Apellis Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how safe and tolerable the drug pegcetacoplan (Syfovre) is for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 300 patients who are already prescribed the drug by their doctor will be followed to track side effects and how the drug is used in real life. The goal is to understand treatment patterns and safety outside of a controlled clinical trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration dry age related macular degeneration Geographic Atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GEOGRAPHIC ATROPHY

Contacts and locations

Locations

Bay Area Retina Associates (01-005)

Walnut Creek, California, 94598, United States
Black Hills Regional Eye Institute (01-010)

Rapid City, South Dakota, 57701, United States
California Retina Consultants (01-026)

Bakersfield, California, 93309, United States
California Retina Consultants (01-027)

Santa Barbara, California, 93103, United States
Colorado Retina Associates, PLLC (01-011)

Lakewood, Colorado, 80228, United States
Cumberland Valley Retina Consultants, P.C. (01-002)

Hagerstown, Maryland, 21740, United States
Georgia Retina (01-032)

Marietta, Georgia, 30060, United States
Illinois Retina Associates (01-035)

Fullerton, California, 92835, United States
Illinois Retina Associates (01-037)

Oak Park, Illinois, 60304, United States
Integrated Clinical Research (01-024)

Abilene, Texas, 79606, United States
Long Island Vitreoretinal Consultants (01-013)

Westbury, New York, 11590, United States
Mid Atlantic Retina (01-001)

Bethlehem, Pennsylvania, 18017, United States
Mid Atlantic Retina (01-031)

Cherry Hill, New Jersey, 08906, United States
Mid Atlantic Retina Research (01-014)

Cherry Hill, New Jersey, 08034, United States
Mid Atlantic Retina Specialist (01-029)

Hagerstown, Maryland, 21740, United States
OCLI Research Department (01-007)

Oceanside, New York, 11572, United States
Pacific Northwest Retina (01-036)

Bellevue, Washington, 98004, United States
Retina Associates of Cleveland, Inc. (01-016)

Youngstown, Ohio, 44505, United States
Retina Associates of Cleveland, Inc. (01-017)

Cleveland, Ohio, 44122, United States
Retina Associates of Cleveland, Inc. (01-022)

Cleveland, Ohio, 44130, United States
Retina Consultants San Diego Inc. (01-018)

Poway, California, 92064, United States
Retina Consultants of Minnesota, PLLC (01-025)

Edina, Minnesota, 55435, United States
Retina Consultants of Texas (01-003)

The Woodlands, Texas, 77384, United States
Retina Consultants of Texas (01-004)

Bellaire, Texas, 77401, United States
Retina Specialty Institute (01-019)

Pensacola, Florida, 32503, United States
Retina-Vitreous Associates Medical Group (01-020)

Beverly Hills, California, 90211, United States
Retinal Consultants Medical Group Inc (01-008)

Modesto, California, 95356, United States
South East Retina Center, PC (01-030)

Augusta, Georgia, 30909, United States
Tennessee Retina (01-033)

Nashville, Tennessee, 37203, United States
Texas Retina Associates (01-028)

Dallas, Texas, 75231, United States
The Retina Care Center (01-023)

Baltimore, Maryland, 21209, United States
The Retina Care Center (01-034) - Satellite Site

York, Pennsylvania, 17402, United States
The Retina Group of Washington (01-021)

Fairfax, Virginia, 22031, United States
Western Carolina Retinal Associates, PA (01-009)

Asheville, North Carolina, 28803, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.